We recently published 10 Big Names Bleed Double Digits. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the ...

September S&P 500 E-Mini futures (ESU25) are trending up +0.24% this morning as investors digested U.S. President Donald ...

Vertex Pharmaceuticals stock sold off on two pipeline disappointments. The biotech company continues to grow with promising ...

Major indexes fell Tuesday as stocks gave back a chunk of the previous session's gains amid ongoing concerns about tariffs and the economic outlook.

The S&P 500 declined 0.5% on Tuesday, Aug. 5, 2025, as a key gauge of the services sector showed a slump in July and trade ...

Vertex Pharmaceuticals Inc.’s bad news from a phase II pain study and separately on the regulatory front caused shares ...

The Dow Jones Industrial Average ended the day 0.1% lower, or around 62 points. The 30-stock index closed below its 21-day ...

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial ...

Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic ...

In connection with earnings, Vertex announced topline results from the Phase 2 study evaluating the safety and efficacy of VX ...

Key Takeaways U.S. equities declined at midday following a soft services industry report and President Donald Trump's ...

Vertex Pharmaceuticals Incorporated (VRTX) is currently at $389.64, down $82.63 or 17.5% --Would be lowest close since Dec. 12, 2023, when it closed at $357.73 --On pace for largest percent decrease ...